Myopathy in scleroderma and in other connective tissue diseases

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Purpose of review This review discusses the most updated literature of myopathy in scleroderma and other connective tissue diseases. Recent findings In the past year, studies have demonstrated that myopathy in scleroderma is associated with poor outcomes such as disability and mortality. In addition, muscle histopathology in scleroderma continues to reveal that it is a heterogeneous entity, and that necrosis and acute neurogenic atrophy may be a more prevalent histopathologic feature in muscle biopsies than previously reported. In other connective tissue diseases such as SLE, the onset of overlap myositis typically does not occur simultaneously as it does in scleroderma or rheumatoid arthritis. Summary Myopathy in scleroderma is heterogeneous and given that it is associated with poor outcomes, it is imperative that optimal diagnostic strategies and therapies including a classification criterion be developed. In other connective tissue diseases, such as rheumatoid arthritis and systemic lupus erythematosus, myopathy is even more poorly defined and requires more robust studies to clarify both the clinical features and muscle histopathology in this group.

Original languageEnglish (US)
Pages (from-to)631-635
Number of pages5
JournalCurrent Opinion in Rheumatology
Issue number6
StatePublished - Oct 1 2016


  • Connective tissue diseases
  • Myopathy
  • Myositis
  • Scleroderma

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Myopathy in scleroderma and in other connective tissue diseases'. Together they form a unique fingerprint.

Cite this